Melanoma referral centers worldwide adopt systemic therapies, reduce lymph node removal surgeries

Providers quickly integrated systemic medications to treat high-risk melanoma into their care after clinical trial results showed their efficacy while simultaneously forgoing lymph node removal surgeries.

9:45 AM

Author | Mary Clare Fischer

Multi color of microscopic Cancer cells
Metastatic melanoma cells. Photograph courtesy of the National Cancer Institute

Lymph node removal surgery for patients with high-risk melanoma has become less common over the past few years while the use of targeted and immune therapies developed through clinical trials to treat the dangerous skin cancer has risen rapidly at melanoma referral centers worldwide, an international group of researchers found.

However, a large degree of variation remained in the treatments providers chose to give to patients that could not be explained by the severity of their cancer, according to the recent study by the International High-Risk Melanoma Consortium.

MORE FROM THE LAB: Subscribe to our weekly newsletter

Over the past five years, clinical trials have shown that systemic medications, including those that harness the immune system like pembrolizumab and ipilimumab, are effective in treating stage III melanoma. Other recent research has revealed that lymph node removal surgeries may be less effective for these patients than previously thought.

SEE ALSO: Why So Many Promising New Cancer Drugs Fail in Clinical Trials

The surgeons at 21 melanoma referral centers collaborated to see whether these revelations had created changes in treatment plans for high-risk melanoma. It can often take significant time as long as a decade for providers to adopt or deescalate cancer treatments, even if the available evidence supports a shift in the landscape. (This lag can stem from a variety of factors, such as poor dissemination of study results and providers' uncertainty about how trial results may apply to specific patients.)

Melanoma programs did implement these practice changes differently, such that treatment a patient received depended a lot on where they were treated
Lesly Dossett, M.D.

In this case, though, the consortium saw signs that melanoma providers not only knew about the latest research but were also applying it in their practices.

"What this study shows is that, unlike the pace of adoption that we see for many scientific innovations, these research findings were adopted very quickly and quite broadly at major melanoma referral centers across the world," said Kristy K. Broman, M.D., M.P.H., an assistant professor of surgery at the University of Alabama at Birmingham and the first author of the study. "We think this may be related to the potential lifelong complications of lymph node removal surgery, which surgeons and patients alike would readily choose to avoid when the surgery is unnecessary, as well as how effective the new systemic treatments are in a landscape where, only 10 years ago, we had no effective systemic therapies."

"It's great to see the fast pace of adoption of new data after major randomized clinical trials are published," says Jonathan Zager, M.D., chief academic officer, senior member, professor and the director of regional therapies at the Moffitt Cancer Center's Donald A. Adam Comprehensive Melanoma Research Center and a co-senior author of the study.

"Yet, as we can see from the data, melanoma programs did implement these practice changes differently," said Lesly Dossett, M.D., the division chief of surgical oncology at University of Michigan Health and a co-senior author of the study, "such that treatment a patient received depended a lot on where they were treated."

SEE ALSO: Who Might Benefit from Immunotherapy? Study Suggests Possible Marker

This variation in melanoma treatment may be due in part to differences in regulations and health insurance systems in the United States compared to Europe and Australia. But it's likely that the individual preferences of physicians play a role as well.

In the future, the researchers plan to delve further into the nuances of decision-making for high-risk melanoma treatments, including factors like the structure of health care teams and organizations and how information is communicated in different health systems.

Like Podcasts? Add the Michigan Medicine News Break on iTunes or anywhere you listen to podcasts.

Paper cited: "International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node Positive Melanoma at Major Referral Centers," Annals of Surgery. DOI: 10.1097/SLA.0000000000005370


More Articles About: Industry DX Melanoma Cancer Surgery Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

This article is from the Health Lab digital publication.

Media Contact Public Relations

Department of Communication at Michigan Medicine

MichMedmedia@med.umich.edu

734-764-2220

Newsletter

Get a weekly digest of medical research and innovation, straight to your inbox.

Subscribe
Featured News & Stories microscope cells glioma
Health Lab
Researchers circumvent radiation resistance in subtype of brain tumors
University of Michigan Rogel Cancer Center researchers find ZMYND8 gene plays a critical role in conferring radiation resistance on brain tumors with IDH1 mutation.
older man holding hands up over head celebrating in hospital bed
Health Lab
Rebounding at 87 after CNS lymphoma
William Moldwin published a book, won awards and is making more plans for his future.
VAD heart device cooler red and teal
Health Lab
Medicare policy change could increase inequity in heart transplant access, study finds
Patients seen at transplant centers had almost 80% higher odds to receive “bridge-to-transplant” designation
machine green laser grid metal
Health Lab
Tracking radiation treatment in real time promises safer, more effective cancer therapy
Radiation, used to treat half of all cancer patients, can be measured during treatment for the first time with precise 3D imaging developed at the University of Michigan.
Mouse model of human colorectal cancer
Health Lab
High levels of ammonia in colon tumors inhibits T cell growth and response to immunotherapy
In mouse models and serum samples, an FDA-approved drug that lowers ammonia levels made the tumors more sensitive to treatment.
Graphic of a surgery table with Lab Note in the upper left corner.
Health Lab
Black patients more likely to get emergency colorectal cancer surgery
Emergency surgery was linked to less thorough pre-surgical assessments and worse outcomes after surgery.